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Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast
cancers.
Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931
patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses.
Tumors with ‡10% nuclear-stained cells were considered positive for AR.
Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size,
well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs),
and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human
epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was
positively related to survival in ER-positive but not in ER-negative tumors. In Cox’s models, AR was an independent
prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER
negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on
survival in patients with TNBC.
Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes
in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine
responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
Key words: androgen receptor, breast cancer, estrogen receptor, molecular apocrine, prognosis
introduction
Recently, it has been suggested that androgen receptor (AR) has
an emerging role in patients with breast cancer [1, 2]. The
molecular mechanisms of AR signaling pathway in breast
cancer biology are not clearly understood, but a significant
number of patients with breast cancer express AR in a primary
or metastatic setting [3, 4]. A few retrospective case–control
studies have demonstrated the important prognostic or
predictive role of AR both in estrogen receptor (ER)-positive
and in ER-negative tumors [5, 6]. Furthermore, AR expression
is observed in patients with triple-negative breast cancer
(TNBC) who have limited therapeutic options, and it has been
implied that AR could be used as a therapeutic target for these
patients [3, 7].
Serum androgen is a precursor for estrogen biosynthesis and
also acts directly via AR. This complexity may make it difficult
to define the role of AR in breast cancers. In vitro models
demonstrate both stimulatory and inhibitory effects of
androgen on growth of various breast cancer cell lines, and
epidemiological evidence has shown controversial associations
between serum androgen levels and risk for breast cancer [7–9].
Therefore, dual impacts of androgen and AR have been
proposed that androgen might act as an estrogen antagonist in
premenopausal patients with a highly estrogenic milieu and, by
contrast, dehydroepiandrosterone (DHEA) would be more
likely to serve as an estrogen agonist in postmenopausal women
with much lower serum estradiol levels [9, 10]. In addition,
because breast cancer is considered to be a heterogeneous
disease demonstrated by gene expression profiling [11], all
patients with breast cancer are not expected to have
a consistently positive or negative reaction to AR as shown in
those with prostate cancer [12]. To improve outcomes, it is
important not only to define the role of AR in breast cancer
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patients but also to identify the subgroups that (i) react
positively to AR, enhancing AR signaling pathways, and (ii)
react negatively to AR, blocking these pathways.
A molecular apocrine breast tumor is one of subgroups
having a possible advantage from blocking AR signaling. This
subtype is characterized by apocrine features upon histological
examination, ER-negative and AR-positive tumors, and a high
association with human epidermal growth factor receptor type
2 (HER2) amplification [13]. Subsequent studies demonstrate
that the molecular apocrine subtype is regulated in an AR-
dependent and ER-independent manner and a functionally
significant cross talk appears to be present between AR and
HER2 pathways [14, 15]. A combined blockade of AR and
HER2 signaling may provide therapeutic synergy to those with
the molecular apocrine subtype [15].
The aims of this study were to investigate the association
between AR expression and clinicopathological parameters and
to evaluate the implications of AR expression in patients with
breast cancer, including stratified analyses by ER status.
patients and methods
patient selection and analysis of clinicopathological
parameters
We prospectively collected tumor tissues from specimens of surgically
resected breast carcinoma at the Department of Surgery, Yonsei University
College of Medicine, between November 1999 and August 2005. All tumor
tissues were fixed in 10% buffered formalin and embedded in paraffin.
Archival hematoxylin and eosin (H&E)-stained slides for each case were
reviewed by two pathologists who specialize in breast pathology and have
extensive experience. The interpretation of immunohistochemistry (IHC)
results was carried out blindly, without any information regarding clinical
parameters or outcome. Patients with pure in situ carcinoma of the breast,
recurrent or metastatic disease, bilateral breast cancers, or non-epithelial-
origin breast cancer such as phyllodes tumor, sarcoma, or lymphoma, as
well as those receiving neoadjuvant chemotherapy, were excluded. Patients
with invasive breast carcinoma who did not present an invasive focus by
review of archival H&E-stained slides were also excluded. Among a total
study population of 1153, after additional exclusion of 13 cases with
unreadable AR expression, 931 patients with invasive breast carcinoma were
finally enrolled. This study was reviewed and approved by the Institutional
Review Board of Severance Hospital, Yonsei University Health System,
Seoul, Korea (4-2010-0136).
Data regarding patient demographics, histopathology of the primary
tumor, treatment patterns, and survival were retrospectively obtained by
reviewing medical records. The type of surgery and adjuvant therapies were
determined not by AR expression but by international guidelines. Patients
were treated with either mastectomy or breast-conserving surgery and
sentinel lymph node biopsy or axillary lymph node dissection. After
surgery, local radiotherapy or adjuvant systemic treatments were
administered if the patient was able to tolerate it. Clinical follow-up
included history taking, physical examination, laboratory tests, and
radiological imaging tests every 6–12 months for detection of relapse.
Tumor stage was based on the American Joint Committee on Cancer 6th
edition criteria. Histological grade was assessed by the modified Bloom–
Richardson classification.
Local recurrence was defined as the reappearance of carcinoma in the
treated remnant breast, skin, or chest wall. Events determining regional
relapse were defined as recurrences to the ipsilateral axillary,
supraclavicular, or internal mammary lymph nodes. Any recurrence at
a distant site including the contralateral axillary or supraclavicular lymph
nodes was considered to be distant metastasis. Disease-free survival (DFS)
time was measured from the date of the first curative surgery to the date of
the first locoregional or systemic relapse, or death without any type of
relapse. Overall survival (OS) time was calculated from the date of the first
definite operation to the date of the last follow-up, or death from any cause.
tissue microarray blocks and immunohistochemical
staining
Formalin-fixed, paraffin-embedded tissue blocks were arrayed using
a tissue-arraying instrument (AccuMax Array; Petagen Inc., Seoul,
Korea). Briefly, representative areas of each tumor were selected and
marked on the H&E slide by breast pathologists. The designated zone of
each donor block was punched with a tissue cylinder 3 mm in diameter and
the sample was transferred to a recipient block in a grid pattern.
Immunohistochemical staining was carried out in the tissue microarray
blocks. Thick sections of 5 lm were obtained with a microtome, transferred
into adhesive slides, and dried at 62C for 30 min. After deparaffinization
and rehydration, the sections were treated with a 3% hydrogen peroxide
solution for 10 min to block endogenous peroxidase and then pretreated for
antigen retrieval in 10 mM citrate buffer (pH 6.0) in a microwave oven for
20 min. After incubation with primary antibodies against AR (AR 441;
Thermo Scientific, Fremont, CA), ER (SP1; Thermo Scientific),
progesterone receptor (PgR 636; DAKO, Glostrup, Denmark), HER2
(polyclonal; DAKO), and Ki-67 (MIB-1; DAKO), immunodetection was
carried out with biotinylated anti-mouse/rabbit immunoglobulin, followed
by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit
with 3,3’-diaminobenzidine chromogen as the substrate. Slides were
counterstained with Harris hematoxylin. Normal breast tissue entrapped
within the block and appropriate control tissues were used as positive
controls.
Tumors with ‡10% positively nuclear-stained cells were considered
positive for AR, ER, PgR, and Ki-67 expression. HER2 staining was scored
by counting the number of positively stained cells on the membrane and
expressed as a percentage of total tumor cells according to the American
Society of Clinical Oncology (ASCO) and the College of American
Pathologists (CAP) guidelines [16] using the following categories: 0, no
immunostaining; 1+, weak incomplete membranous staining in any
proportion of tumor cells; 2+, complete membranous staining, either
nonuniform or weak in at least 10% of tumor cells; and 3+, uniform intense
membranous staining in >30% of tumor cells. HER2 results were
considered positive in cases with 3+ membranous staining of IHC or gene
amplification by FISH regardless of the IHC results using the diagnostic
criteria described in the following. TNBC was defined as a tumor showing
negative expression for ER, PgR, and HER2 by IHC or FISH.
fluorescence in situ hybridization
FISH analysis using the PathVysion HER2 DNA Probe Kit (Abbott, Abbott
Park, IL) was carried out manually in all patients. In brief, consecutive
sections from formalin-fixed, paraffin-embedded tissue microarray blocks
were mounted on ProbeOn Plus microscope slides (Fisher Scientific,
Pittsburgh, PA), deparaffinized in xylene, and subsequently rehydrated in
ethanol. They were then boiled for 10 min in pretreatment solution,
incubated with pepsin solution for 10 min, dehydrated in ethanol for 6 min,
and finally air-dried. For hybridization, the buffered probe (HER2/neu and
centromere 17) was introduced onto the slide and protected by a coverslip
sealed with rubber cement. For denaturation, slides were heated to 82C
and incubated overnight at 45C in a dark humidified chamber. The rubber
cement and coverslip were then removed, and the slides were transferred to
stringent wash buffer for 10 min at 65C. Afterward, they were dehydrated
in ethanol for 6 min and air-dried. Finally, they were counterstained with
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4#,6-diamidino-2-phenylindole (DAPI). Evaluation of signals was carried
out using an epifluorescence microscope (Olympus, Tokyo, Japan)
equipped with a fluorescein, Cy3, and a DAPI filter set and a 100-W
mercury lamp. Counting was carried out according to the manufacturer’s
manual (the HER2/neu gene appeared as orange and centromere 17 as
green). As recommended by the ASCO/CAP guideline [16], an absolute
HER2 gene copy number >6 or HER2 gene/chromosome 17 copy number
ratio higher than 2.2 was considered HER2 positive. Lymphocytes,
fibroblasts, and normal ductal epithelial cells were used as internal controls.
statistical analysis
The differences between the groups were evaluated by a chi-square test.
Fisher’s exact test was used when appropriate. Survival curves were
determined and plotted using the Kaplan–Meier method and group
differences in survival time were investigated by a log-rank test. A Cox
proportional hazards model was used to identify variables that were
independently associated with survival. All statistical tests were two-sided,
and P values of <0.05 were considered statistically significant. SPSS for
Windows version 17.0 (SPSS Inc., Chicago, IL) was used for all statistical
analyses.
results
characteristics and outcomes in all patients
The mean age at diagnosis was 49.3 years [standard deviation
(SD) 10.5 years] for all patients. AR expression was
demonstrated in 58.1% (541 of 931) of patients. Positive
expression of ER, PgR, and HER2 was observed in 72.2% (n =
672), 61.4% (n = 572), and 24.7% (n = 230) of patients,
respectively. The clinicopathological characteristics according
to AR expression in all patients are summarized in Table 1.
Patients with AR-positive tumor showed a higher frequency of
age over 35 years at diagnosis. A significant number of AR-
positive tumors were associated with lower pathological tumor
stage, grade I or II tumors, and lower proliferative Ki-67 index.
AR was significantly expressed in ER-positive, PgR-positive,
and non-TNBC tumors. Among our study population, 68.7%
(474 of 690) of patients with endocrine-responsive tumor (ER-
positive and/or PgR-positive tumor) expressed AR. However,
27.8% (67 of 241) of patients with endocrine-nonresponsive
tumor (ER-negative and PgR-negative tumor) and 13.5% (21
of 156) of patients with TNBC expressed AR. No statistical
difference was demonstrated in AR expression according to
pathological nodal stage, HER2 overexpression, and
locoregional treatment modalities. Patients with AR-negative
tumor more frequently received adjuvant systemic
chemotherapy, whereas those with AR-positive cancer were
more often administered endocrine therapy.
With a mean follow-up duration of 72.7 months (SD 22.6
months), AR expressionwas a significant prognostic factor forDFS
andOS in all patients (Figure 1). The 5-yearDFS andOSof patients
with AR-positive tumor were 88.2% and 93.8%, respectively. The
5-year DFS and OS of those with AR-negative tumor were 83.7%
and 90.1%, respectively. AR expression was positively associated
with survival outcomes in all patients. However, in the Cox
regression models for DFS and OS, statistical significance
disappeared when adjusting for age at diagnosis, pathological
tumor and nodal stage, ER status,HER2 overexpression, and use of
chemoendocrine therapy (data not shown).
characteristics and outcomes stratified by ER
status
The patient and tumor characteristics stratified by ER
expression are shown in Table 2. AR expression was determined
in 69.9% (470 of 672) of patients with ER-positive breast cancer
Table 1. Patient demographics
Factor AR negative,
n = 390 (%)
AR positive,
n = 541 (%)
P value
Age (years)
£35 39 (10.0) 29 (5.4) 0.007
>35 351 (90.0) 512 (94.6)
Pathological T stage
T1 150 (38.5) 303 (56.0) <0.001
T2 229 (58.7) 232 (42.9)
T3–4 11 (2.8) 6 (1.1)
Pathological N stage
N0 214 (54.9) 315 (58.2) 0.260
N1 108 (27.7) 140 (25.9)
N2 35 (9.0) 56 (10.4)
N3 33 (8.5) 30 (5.5)
Histological grade
I 49 (12.6) 131 (24.2) <0.001
II 177 (45.4) 312 (57.7)
III 164 (42.1) 98 (18.1)
Estrogen receptor
Negative 188 (48.2) 71 (13.1) <0.001
Positive 202 (51.8) 470 (86.9)
Progesterone receptor
Negative 223 (57.2) 136 (25.1) <0.001
Positive 167 (42.8) 405 (74.9)
HER2
Negative 303 (77.7) 398 (73.6) 0.150
Positive 87 (22.3) 143 (26.4)
Triple-negative breast cancera
No 255 (65.4) 520 (96.1) <0.001
Yes 135 (34.6) 21 (3.9)
Ki-67 (%, n = 929)
<10 153 (39.2) 376 (69.8) <0.001
‡10 237 (60.8) 163 (30.2)
Type of surgery
BCS 108 (27.7) 162 (29.9) 0.455
TM 282 (72.3) 379 (70.1)
Radiotherapy
Not done 225 (57.7) 305 (56.4) 0.689
Done 165 (42.3) 236 (43.6)
Chemotherapy
Not done 51 (13.1) 111 (20.5) 0.003
Done 339 (86.9) 430 (79.5)
Endocrine therapy
Not done 195 (50.0) 106 (19.6) <0.001
Done 195 (50.0) 435 (80.4)
aTriple-negative breast cancer represents tumors showing negative
expression for estrogen receptor, progesterone receptor, and HER2 by
immunohistochemistry or FISH.
AR, androgen receptor; T, tumor; N, node; HER2, human epidermal
growth factor receptor type 2; BCS, breast-conserving surgery; TM, total
mastectomy.
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and in 27.4% (71 of 259) of those with ER-negative tumor. In
patients with ER-positive tumor, AR expression was
significantly associated with smaller tumor size, nodal
uninvolvement, grade I or II tumors, higher PgR expression,
and lower proliferation index. In patients with ER-negative
cancer, however, AR expression was statistically related to well
differentiation, lower Ki-67 index, and distinctively HER2
overexpression. Locoregional and adjuvant treatment
modalities according to AR expression in ER-positive and ER-
negative tumors, respectively, are summarized in Table 2.
The DFS and OS according to AR expression in patients with
ER-positive and ER-negative tumors, respectively, are
presented in Figure 2. In patients with ER-positive tumor, AR
expression was positively associated with DFS and OS (Figure
2A and B), as shown in all patients with statistical significance.
However, in ER-negative breast cancers, there was no
significant difference in survival according to AR expression.
AR-positive tumors presented a trend toward relatively poorer
outcomes (Figure 2C and D). In the multivariate Cox’s models,
AR expression was an independent prognostic factor for DFS
(hazard ratio, 0.654; P = 0.049), but it did not have statistical
significance for OS (hazard ratio, 0.647; P = 0.119) in patients
with ER-positive cancers when adjusting for age at diagnosis,
pathological tumors and nodal stage, HER2 overexpression,
and use of chemoendocrine therapy (Table 3). In ER-negative
tumors, pathological tumor stage, nodal stage, and use of
chemotherapy were independent prognostic factors for survival
outcomes (Table 4). AR expression distinctively increased in
hazard ratio without statistical significance in the multivariate
analyses.
outcomes of subgroups with ER-negative tumor
The implications of AR expression on breast cancer outcome
were investigated in the subgroup of patients with ER-negative
tumor. As shown in Table 2, 53.8% (49 of 91) of patients with
ER-negative and HER2-positive tumors expressed AR. The DFS
and OS of 91 patients with ER-negative and HER2-positive
tumors are presented in Figure 3 according to AR expression.
Interestingly, tumors with molecular apocrine features (ER-
negative, AR-positive, and HER2-positive tumors) showed
a trend of poorer DFS (P = 0.483) and OS (P = 0.074).
However, in our study population, only 13.5% of patients with
TNBC expressed AR (Table 1), and there was no impact of AR
expression on the survival of the 156 patients with TNBC
(Figure 4).
discussion
Breast cancer is a highly hormone-dependent tumor. The role
of estrogen and its receptor is well established in the
carcinogenesis and tumor progression; therefore, indirect or
direct inhibition of ER pathways is the mainstay for treatment
of breast carcinoma [17]. Although androgen is a dominant
steroid hormone throughout a woman’s life and a necessary
precursor for estrogen biosynthesis, AR has only recently been
considered as an emerging biomarker in breast cancer [2, 9].
AR is expressed in >60%–70% of both in situ and invasive
breast cancers and is frequently coexpressed with ER and PgR
but rarely with HER2 [18, 19]. In the present study, we also
demonstrated an association between AR expression and
favorable clinicopathological parameters, which is consistent
with our own previous study as well as others [3, 18–20]. AR
expression was observed in significant levels in endocrine-
responsive tumors including non-TNBC. Of note, however, is
that approximately one-fourth of patients with ER-negative
tumors also expressed AR. There was no significant interaction
between AR and HER2 in all patients of this study.
The prognostic role of AR in breast cancer patients has
recently been suggested [5, 6, 21]. Our results showed an
important implication of AR in all study population. In
univariate analyses, AR was a significant factor for survival
outcome. After controlling for well-established prognostic
factors including ER status, however, AR was found to have no
independent statistical significance. Because previous studies
have proposed a contradictory hypothesis according to
estrogenic milieu [9], we analyzed the prognostic significance of
AR according to ER expression status.
In patients with ER-positive tumor, AR expression was
significantly associated with better prognostic markers as
shown in all patients. In addition, the prognostic significance of
AR was demonstrated in multivariate analyses for DFS but not
for OS. These results were consistent with previous reports [5,
Figure 1. Disease-free (A) and overall (B) survival according to androgen receptor (AR) expression in all patients.
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20, 21]. Although we did not consider types or regimens of
systemic therapies in this study, AR might provide an
additional predictive role for systemic treatments including
endocrine therapy because 90.2% (606 of 672) of our ER-
positive subgroup received endocrine therapy or
chemoendocrine therapy. The in vitro study suggests
a significant inhibitory interaction between ER and AR [21],
and that potential therapeutic effects of aromatase inhibitors
may be due not only to a reduction in estrogen levels but also to
an increase in inhibitory AR signaling pathways [22]. Another
large retrospective study demonstrated a prognostic and
predictive role of AR in the subset of ER-positive tumors [5].
Taken together, AR expression could be an additional
significant biomarker for endocrine responsiveness in ER-
positive cancers, and further prospective study is necessary to
determine the role of AR in patients with ER-positive tumors.
There have been limited data regarding AR in ER-negative
breast cancers. Most studies have determined higher expression
rates of AR in ER-positive tumors; however, as many as half of
the ER-negative tumors expressed AR [3, 5, 6]. The present
study showed positive AR expression in 30% of ER-negative
cancers, which is lower than that of our previous report on AR
positivity in the ER-negative subgroup [3]. There was
statistically no prognostic impact of AR in our ER-negative and
TNBC subset; there was however a trend showing an inverse
relationship between AR expression and clinical outcome for
ER-negative tumors.
Approximately one-third of breast cancer cases are
constituted by ER-negative tumors, and these patients do not
benefit from endocrine therapy and show a poorer prognosis
than patients with ER-positive tumor [17]. Among ER-negative
breast cancers, however, active AR signaling was demonstrated
in the molecular apocrine tumors as described by Farmer et al.
[13] in 2005. Subsequent study showed that this subgroup was
characterized by AR-dependent, androgen-regulated
transcriptional program and by significant interaction between
Table 2. Patient demographics stratified by estrogen receptor (ER) expression
Factor ER positive (n = 672) ER negative (n = 259)
AR negative,
n = 202 (%)
AR positive,
n = 470 (%)
P value AR negative,
n = 188 (%)
AR positive,
n = 71 (%)
P value
Age (years)
£35 17 (8.4) 24 (5.1) 0.100 22 (11.7) 5 (7.0) 0.274
>35 185 (91.6) 446 (94.9) 166 (88.3) 66 (93.0)
Pathological T stage
T1 82 (40.6) 277 (58.9) <0.001 68 (36.2) 26 (36.6) 0.946
T2–4 120 (59.4) 193 (41.1) 120 (63.8) 45 (63.4)
Pathological N stage
N0 92 (45.5) 275 (58.5) 0.002 122 (64.9) 40 (56.3) 0.204
N1–3 110 (54.5) 195 (41.5) 66 (35.1) 31 (43.7)
Histological grade
I/II 156 (77.2) 404 (86.0) 0.005 70 (37.2) 39 (54.9) 0.010
III 46 (22.8) 66 (14.0) 118 (62.8) 32 (45.1)
Progesterone receptor
Negative 49 (24.3) 69 (14.7) 0.003 174 (92.6) 67 (94.4) 0.786
Positive 153 (75.7) 401 (85.3) 14 (7.4) 4 (5.6)
HER2
Negative 157 (77.7) 376 (80.0) 0.504 146 (77.7) 22 (31.0) <0.001
Positive 45 (22.3) 94 (20.0) 42 (22.3) 49 (69.0)
Ki-67 (%)
<10 128 (63.4) 350 (74.8) 0.003 25 (13.3) 26 (36.6) <0.001
‡10 74 (36.6) 118 (25.2) 163 (86.7) 45 (63.4)
Type of surgery
BCS 41 (20.3) 146 (31.1) 0.004 67 (35.6) 16 (22.5) 0.044
TM 161 (79.7) 324 (68.9) 121 (64.4) 55 (77.5)
Radiotherapy
Not done 125 (61.9) 264 (56.2) 0.169 100 (53.2) 41 (57.7) 0.511
Done 77 (38.1) 206 (43.8) 88 (46.8) 30 (42.3)
Chemotherapy
Not done 27 (13.4) 95 (20.2) 0.035 24 (12.8) 16 (22.5) 0.052
Done 175 (86.6) 375 (79.8) 164 (87.2) 55 (77.5)
Endocrine therapy
Not done 27 (13.4) 39 (8.3) 0.043 168 (89.4) 67 (94.4) 0.215
Done 175 (86.6) 431 (91.7) 20 (10.6) 4 (5.6)
AR, androgen receptor; T, tumor; N, node; HER2, human epidermal growth factor receptor type 2; BCS, breast-conserving surgery; TM, total mastectomy.
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AR and HER2 signaling [14, 15, 20, 23]. These associations
have also been suggested by morphological studies of breast
lesions. Morphologically, tumors with apocrine differentiation
frequently showed ER-negative, AR-positive, and HER2-
positive features [20, 24–26]. We previously described
a possible correlation between AR and HER2 in these special
subsets [3]. Using the independent dataset of ER-negative
tumors, a statistically significant association between AR
Figure 2. Survival curves stratified by estrogen receptor status. (A) Disease-free and (B) overall survival according to androgen receptor (AR) expression in
patients with estrogen receptor-positive tumor. Panels C and D show the same in patients with estrogen receptor-negative tumor. ER, estrogen receptor.
Table 3. Multivariate analysis in patients with estrogen receptor-positive tumor
Factor Disease-free survival Overall survival
Hazard
ratio
95% CI P value Hazard
ratio
95% CI P value
Androgen receptor
Negative versus positive 0.654 0.429–0.997 0.049 0.647 0.375–1.119 0.119
Age (years)
£35 versus >35 0.496 0.260–0.946 0.033 0.434 0.197–0.954 0.038
Pathological T stage
T1 versus T2–4 1.622 1.011–2.602 0.045 2.108 1.109–4.008 0.023
Pathological N stage
N0 versus N1–3 2.456 1.501–4.020 <0.001 2.167 1.154–4.070 0.016
HER2
Negative versus positive 2.004 1.278–3.140 0.002 1.555 0.850–2.845 0.152
Chemotherapy
Not done versus done 0.419 0.232–0.756 0.004 0.298 0.145–0.611 0.001
Endocrine therapy
Not done versus done 1.147 0.583–2.256 0.691 1.001 0.436–2.297 0.998
CI, confidence interval; T, tumor; N, node; HER2, human epidermal growth factor receptor type 2.
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expression and HER2 positivity was again demonstrated
(Table 2) in addition to a borderline significantly poorer OS in
the ER-negative, HER2-positive subset with AR expression
(Figure 3). Although there were limitations that kept our study
from including a retrospective analysis with a small sample size,
it supports the idea that blockading both AR and HER2
pathways might be a rational and useful therapeutic option for
this subgroup. Because many antiandrogenic agents, including
Table 4. Multivariate analysis in patients with estrogen receptor-negative tumor
Factor Disease-free survival Overall survival
Hazard
ratio
95% CI P value Hazard
ratio
95% CI P value
Androgen receptor
Negative versus positive 1.163 0.601–2.249 0.654 1.451 0.710–2.965 0.307
Age (years)
£35 versus >35 0.920 0.322–2.630 0.877 0.813 0.241–2.742 0.738
Pathological T stage
T1 versus T2–4 2.904 1.240–6.801 0.014 4.324 1.522–12.286 0.006
Pathological N stage
N0 versus N1–3 2.521 1.292–4.919 0.007 3.316 1.535–7.160 0.002
HER2
Negative versus positive 1.026 0.546–1.930 0.936 0.814 0.401–1.655 0.570
Chemotherapy
Not done versus done 0.332 0.135–0.814 0.016 0.192 0.076–0.487 0.001
CI, confidence interval; T, tumor; N, node; HER2, human epidermal growth factor receptor type 2.
Figure 3. Disease-free (A) and overall (B) survival according to androgen receptor (AR) expression in 91 patients with estrogen receptor-negative and
human epidermal growth factor receptor type 2-positive tumor.
Figure 4. Disease-free (A) and overall (B) survival according to androgen receptor (AR) expression in 156 patients with triple-negative breast cancer.
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bicalutamide, are now clinically available and orally active, it is
reasonable to validate the safety and efficacy of antiandrogens
for breast cancer patients [7, 27]. A phase II feasibility study of
bicalutamide in treating patients with metastatic breast cancer
is being conducted (ClinicalTrials.gov identifier;
NCT00468715). The preliminary results have been promising
in demonstrating a high tolerability and possible antitumor
effect of antiandrogen therapy in patients with AR-positive, ER-
negative, and PgR-negative metastatic breast cancer [28].
In summary, the present study suggests that AR expression is
significantly associated with favorable clinicopathological
characteristics and better outcomes in ER-positive breast
cancers. On the contrary, AR is related to growth factor
signaling in ER-negative tumors, and molecular apocrine
tumors show a trend of poorer survival. Taken together, this
indicates that AR expression could be an additional marker for
endocrine responsiveness in ER-positive cancers and a possible
therapeutic target molecule for the ER-negative subgroup,
including molecular apocrine tumors.
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